|
|
|
|
 |
Sequenom Certifies McGill University and Génome Québec Innovation Centre as First Center of Excellence |
| Companies mentioned in this article: |
|
Sequenom, Inc. |
|
| 8/5/2008 @ 6:55 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic analysis solutions, and Génome Québec today announced that the McGill University and Génome Québec Innovation Centre has become the first Center of Excellence certified by Sequenom for genotyping technology. The Center of Excellence certification is a collaborative partner relationship aimed at ensuring high-quality data available from genotyping application using the Sequenom MassARRAY system performed at Génome Québec.
The Center of Excellence distinction signifies the achievement and maintenance of ongoing quality and service excellence for genotyping. In achieving the Center of Excellence certification, Génome Québec was required to pass initial laboratory qualification tests, as well as proficiency tests and operating procedure audits aimed at assessing the quoting process, turnaround time and data delivery capabilities of the organization. During its first year of certification, Génome Québec will have exclusive status as the only Sequenom Genotyping Center of Excellence in Canada.
“We are excited about partnering with an institute of Génome Québec’s stature for our first Center of Excellence,” said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “We will look to expand this program to additional academic and research institutions, which will make it easier to access the high-throughput and cost-effective capabilities of our MassARRAY technology.”
Senior Director of Operations and Business Development of the McGill University and Génome Québec Innovation Centre, Daniel Tessier, stated, “We are delighted to partner with Sequenom and this certification confirms the high-quality standards we have set for the Innovation Centre’s sequencing and genotyping services. We are especially proud of the Center of Excellence certification because we participated in the creation of the program and its implementation.”
Paul L’Archevêque, President and CEO of Génome Québec, added, “This is another important move forward for Génome Québec and, by extension, for the international recognition of Québec’s genomics industry. This is a truly tangible result of a long-term partnership with Sequenom.”
McGill University and Génome Québec Innovation Centre operates two Sequenom MassARRAY compact instruments. Now certified as a Sequenom Genotyping Center of Excellence, Génome Québec will soon begin testing for qualification of Sequenom’s EpiTYPER methylation services.
About the McGill University and Génome Québec Innovation Centre
The McGill University and Génome Québec Innovation Centre is financed by Genome Canada and the ministère du Développement Économique, de l’Innovation et de l’Exportation of Québec, and provides complete DNA analysis services, from a few samples to several tens of thousands per week. Ambitious DNA sequencing projects carried out over the past five years are testimony of Génome Québec’s ability to provide data of exceptional quality in the pursuit of various genomics studies. Large-scale genomics projects at the Innovation Centre are highly integrated together on three platforms: sequencing, genotyping and functional genomics supported by an infrastructure and unique expertise in bioinformatics. High-quality protein separation and analysis services are also provided by the proteomics platform. To find out more, visit the Web site at www.genomequebecplatforms.com/mcgill.
About Génome Québec
Génome Québec is a private non-profit organization whose mission is to reinforce Québec’s innovation system in genomics by financing major genomics research initiatives. The investments of more than 400 million dollars since 2001 have contributed to accelerate the discovery of new applications, such as screening tests, therapeutic tools in human health or new environmental procedures in agriculture and forestry. The funds invested by Génome Québec come from the ministère du Développement économique, de l’Innovation et de l’Exportation of Québec, the Government of Canada through Génome Canada and from private partners. To find out more about Génome Québec and genomics, visit its Web site at www.genomequebec.com.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications, and for research conducted in the agro (agricultural and livestock) industry. The Company’s proprietary MassARRAY system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
